Evidence-based medicine, health costs and intra-abdominal infection treatment;Medicina basada en la evidencia, costes sanitarios y tratamiento de la infección intraabdominal

Enfermedades Infecciosas y Microbiologia Clinica

Volumn 17, Issue SUPPL. 2, 1999, Pages 86-94

  Badía, Xavier ^a   Brosa, Max ^b   Tellado, José M ^c  

^a HOSPITAL UNIVERSITARI DE BELLVITGE   (Spain)

^b Health Outcomes Research Europe   (Spain)

^c HOSPITAL GENERAL UNIVERSITARIO GREGORIO MARAÑÓN   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

AMINOGLYCOSIDE; ANTIINFECTIVE AGENT; CILASTATIN; IMIPENEM; MEROPENEM; THIENAMYCIN DERIVATIVE;

ABDOMEN; ADULT; AGED; ARTICLE; BACTERIAL INFECTION; CHILD; CLINICAL TRIAL; COMPARATIVE STUDY; COST BENEFIT ANALYSIS; DOUBLE BLIND PROCEDURE; DRUG COMBINATION; DRUG COST; ECONOMICS; EVIDENCE BASED MEDICINE; HEALTH CARE COST; HOSPITAL COST; HUMAN; META ANALYSIS; MIDDLE AGED; PROSPECTIVE STUDY; RISK; SINGLE BLIND PROCEDURE; SPAIN; TREATMENT OUTCOME;

ABDOMEN; ADULT; AGED; AMINOGLYCOSIDES; ANTI-BACTERIAL AGENTS; BACTERIAL INFECTIONS; CHILD; CILASTATIN; CLINICAL TRIALS; COST-BENEFIT ANALYSIS; DOUBLE-BLIND METHOD; DRUG COSTS; DRUG THERAPY, COMBINATION; EVIDENCE-BASED MEDICINE; HEALTH CARE COSTS; HOSPITAL COSTS; HUMANS; IMIPENEM; MIDDLE AGED; ODDS RATIO; PROSPECTIVE STUDIES; SINGLE-BLIND METHOD; SPAIN; THIENAMYCINS; TREATMENT OUTCOME;

EID: 0033254676     PISSN: 0213005X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (27)

1. Baños JE, Brotons C, Fairé M. Glosario de investigación clinica y epidemiológica. Fundación Dr. Antonio Esteve, Barcelona 1998.
2. Badía X, Rovira J. Introductión a la evaluatión económica de medicamentos y otras tecnológías sanitarias. Ed. Luzán 5, S.A., Madrid 1995.
3. Ministerio de Sanidad y Consumo. Grupos terapéuticos y principles actives de mayor consumo en el sistema nacional de salud durante 1997. Information terapéutica del Sistema Nacional de Salud 1998; 22:123-125.
4. Chang DC, Wilson SE. Meta-analysis of the clinical outcomes of carbapenems monotherapy in the adjunctive treatment of intraabdominal infections. Am J Surg 1997, 174: 284-290.
5. Azanza JR, Cameán H, Cercós AC. Consenso sobre el diseño de un modelo farmacoeconómico until para la valoración de antibióticos parenterales de uso hospitalario. Revista Española de Farmacoeconomía, Marzo de 1997.
6. Sacristán JA, Badía X, Rovira J. Farmacoeconomía: evaluación económica de medieamentos. Ed. Editores Medicos S.A., Madrid 1995.
7. Colardyn F, Faulkner KL. Intravenous meropenem versus imipenem/cilastatin in the treatment of serious bacterial infections in hospitalized patients. J Antimicrob Chemother 1996, 38: 523-537.
8. Geroulanos SJ. Meropenem versus imipenem/cilastatin in intraabdominal infections requiring surgery. J Antimicrob Chemother 1995; 36 (Suppl A): 191-205.
9. Kanellakopoulou K, Giamarellou H, Papadothomakos P. Meropenem versus imipenem/cilastatin in the treatment of intraabdominal infections requiring surgery. Eur J Clin Microbiol Infect Dis 1993; 12: 449-453.
10. Brismar B, Malmborg AS, Tuvevall G. Meropenem versus imipenem-cilas-tatin for treatment of intraabdominal infections. J Antimicrob Chemother 1995; 35: 139-148.
11. Basoli A, Meli EZ, Mazzocchi P, Speranza V. Imipenem/cilastatin (1,5 g daily) versus meropenem (3,0 g daily) in patients with intraabdominal infections: results of a prospective randomized multicentre trial. Scand J Infect Dis 1997, 29: 503-508.
12. Solomkin JS, Dellmger EP, Christou NV, Busuttil RW. Results of a multi-center trial comparing imipenem/cilastatin to tobramycin/clindamycin for intraabdominal infections. Ann Surg 1990; 212: 581-591.
13. Poenaru D, De Santos M, Christou NV. Imipenem versus tobramycin-antianaerobe antibiotic therapy in intraabdominal infections. Can J Surg Dis 1990; 33:415-422.
14. Mandell LA, Turgeon PL, Ronalds AR. A prospective randomized trial of imipenem-cilastatin versus clindamycin/tobramycin in the treatment of intraabdominal and pelvic infections. Can J Infect Dis 1993; 4:279-287.
15. Gonzenbach HR, Simmen HP, Angwerd R. Imipenem versus netilmicin plus clinamycin. Ann Surg 1987; 205: 271-275.
16. Eckhauser FE, Knol JA, Raper SE. Efficacy of two comparative antibiotic regimens in the treatment of serious intra-abdominal infections: results of a multicenter study. Clin Ther 1992; 14: 97-109.
17. Swedish Study Group. Imipenem-cilastatin vs gentamicin-clindamicin in the treatment of serious bacterial infections. Lancet 1984; 8382: 868-871.
18. Uhari M, Seppanen J, Heikkinen E. Imipenem-cilastatin vs tobramycin and metronidazole for appendicitis-related infections. Pediatr Infect Dis J 1992, 11:445-450.
19. Danzinger LH, Creger RJ, Shwed JA. Randomized trial of imipenem-cilastatin versus gentamicin plus clindamycin in the treatment of polymicrobial infections. Pharmacotherapy 1988, 8(6): 315-318.
20. Solomkin JS, Fant WK, Rivera JO. Randomized trial of imipenem/cilastatin versus gentamicin and clindamycin in mixed flora infections. Am J Med 1985, 78: 85-91.
21. Speranza V, Basoli A: Comparative evaluation of Carbapenems in intraabdominal infection. 8th ECCMID; Lausanne (Switzerland), 1997.
22. Gisbert R, Brosa M. Costes sanitarios y evaluación económics. Soikos S.L.; Barcelona, 1998.
23. Consejo General de Colegios Oficiales de Farmacéuticos. Catálogo General de Especialidades; Madrid, 1998.
24. Benfield P, Chrisp P. Imipenem/Cilastatin: A pharmacoeconomic appraisal of its use in intraabdominal infections. Pharmacoeconomics 1992; 1: 443-459.
25. McCormack JP, Jewesson PJ. A critical reevaluation of the therapeutic range of aminoglycosides. CID 92; 14:320-339.
26. Balfour JA, Bryson HM, Brogden RN. Imipenem/cilastatin: an update of its antibacterial activity, pharmacokinetics and therapeutic efficacy in the treatment of serious infections. Drugs 96; 51: 99-136.
27. Wiseman LR, Wagstaff AJ, Brodgen RN, Bryson HM. Meropenem: a review of its antibacterial activity, parmacokinetics properties and clinical efficacy. Drugs 95; 50: 73-101.